Form D · Biotechnology
HELICON THERAPEUTICS INC
San Diego, CA · CIK 0001133196
Offering snapshot reported Jun 26, 2009 · SEC filing
- Reported sold
- $50M Offering amount: $50M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 22, 2009 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 26, 2009 | Initial | $50,000,000 | No comparison | 1 | SEC filing |
| Oct 11, 2006 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-55393
Source: Form D, filed Jun 26, 2009. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Kenneth Dart | Director |
| Jonathan Gelles, D. Phil. | Director |
| Kenneth E. Johns, Jr. | Director, Executive |
| Tim Tully, Ph D. | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
7473 Lusk Blvd.
San Diego, CA, 92121
San Diego, CA, 92121